INTERVIEW: ImmuPharma plc Positive results and new initiation note

ImmuPharma plc (LON: IMM) Chairman Tim McCarthy joins DirectorsTalk to discuss final results for the twelve months ended 31 December 2018. Tim talks us through the financial highlights, including the loss for the year and cash position. Provides guidance on spend going forward, an update on the pipeline, key milestones for the company over the next 12 months and provides some insight into an initiation note on ImmuPharma with a price target of 92p.

ImmuPharma plc is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. The company is led by a commercially focused Board and management team with extensive experience.

Find more news, interviews, share price & company profile here for:

    You can also listen to our interviews on: 

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp
    Immupharma plc
    INTERVIEW: ImmuPharma plc Positive results and new initiation note

    Other Interviews

    More News

    Ask your questions

    Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

    I have questions